Wedbush Equities Analysts Cut Earnings Estimates for argenex

argenex SE (NASDAQ:ARGX - Free Report) - Equities researchers at Wedbush reduced their Q2 2025 earnings estimates for shares of argenex in a research report issued on Monday, June 16th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $3.43 per share for the quarter, down from their prior estimate of $4.19. Wedbush currently has a "Outperform" rating and a $715.00 target price on the stock. The consensus estimate for argenex's current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex's Q3 2025 earnings at $4.49 EPS, Q4 2025 earnings at $5.43 EPS, Q1 2026 earnings at $6.58 EPS, Q2 2026 earnings at $7.71 EPS, Q3 2026 earnings at $7.21 EPS, FY2026 earnings at $29.33 EPS, FY2027 earnings at $38.72 EPS and FY2028 earnings at $53.89 EPS.

Several other equities analysts also recently commented on the stock. Oppenheimer increased their price objective on shares of argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. HC Wainwright reissued a "buy" rating and issued a $720.00 price objective on shares of argenex in a research note on Tuesday, June 10th. Baird R W raised shares of argenex from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 13th. Robert W. Baird raised shares of argenex from a "neutral" rating to an "outperform" rating and set a $680.00 price objective for the company in a research note on Tuesday, May 13th. Finally, William Blair reissued an "outperform" rating on shares of argenex in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $709.18.

argenex Trading Up 0.8%

NASDAQ:ARGX traded up $4.23 on Wednesday, hitting $542.15. The company had a trading volume of 372,905 shares, compared to its average volume of 325,762. The stock has a market capitalization of $33.10 billion, a price-to-earnings ratio of 33.45, a PEG ratio of 0.98 and a beta of 0.39. The firm has a 50 day moving average of $585.62 and a two-hundred day moving average of $609.06. argenex has a 52 week low of $428.76 and a 52 week high of $678.21.

argenex (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts' consensus estimates of $2.32 by $0.26. argenex had a net margin of 40.20% and a return on equity of 16.15%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million.

Institutional Investors Weigh In On argenex

Several large investors have recently modified their holdings of ARGX. FMR LLC increased its position in shares of argenex by 17.2% during the fourth quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after buying an additional 824,750 shares during the period. Millennium Management LLC increased its position in shares of argenex by 316.9% during the first quarter. Millennium Management LLC now owns 268,604 shares of the company's stock worth $158,977,000 after buying an additional 204,180 shares during the period. Point72 Asset Management L.P. acquired a new stake in argenex in the fourth quarter worth $91,013,000. GAMMA Investing LLC grew its holdings in argenex by 53,684.9% in the first quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock worth $802,200,000 after purchasing an additional 135,286 shares during the period. Finally, Marshall Wace LLP grew its holdings in argenex by 184.7% in the fourth quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock worth $117,805,000 after purchasing an additional 124,271 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.